Stock Market & Financial Investment News

News Breaks February 15, 2013 07:15 EDT PCYC Pharmacyclics price target raised to $96 from $83 at Piper Jaffray Piper Jaffray said Pharmacyclics confirmed the filing for ibrutinib in Mantle Cell Lymphoma, or MCL, by year end, which places the launch one year ahead of Street expectations. The firm raised its price target for shares and keeps an Overweight rating on the name. News For PCYC From The Last 14 Days Check below for free stories on PCYC the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 14:07 EDT PCYC Pharmacyclics drug designated for orphan status for multiple myeloma treatment Subscribe for More Information May 13, 2013 10:09 EDT PCYC On The Fly: Analyst Upgrade Summary Subscribe for More Information 06:33 EDT PCYC Pharmacyclics upgraded to Outperform from Sector Perform at RBC Capital Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.